SCHEMBL13699331

SCHEMBL13699331

CCCN(C(=O)c1ccc(OC2CC3CCC(C2)N3C)cc1)c1ccc(Oc2ccc(NC(=O)NC(CC)CC)cc2OC)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.39
CHRM3 P20309 3/20 0.39
CHRM5 P08912 2/20 0.39
CYP2D6 P10635 2/20 0.39
PKM P14618 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
LPAR1 Q92633 1/20 0.35
LPAR5 Q9H1C0 1/20 0.35
CHRM2 P08172 1/20 0.35
MCHR1 Q99705 4/20 0.35
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699221 0.94 CYP2D6 (0.40) CHRM1CHRM3CHRM5CYP2D6PKM
SCHEMBL13699207 0.91 PKM (0.41) CHRM1CHRM3CHRM5CYP2D6PKM
SCHEMBL13699295 0.91 CYP2D6 (0.37) CHRM1CHRM3CHRM5CYP2D6PKM
SCHEMBL13699144 0.88 SMN1; SMN2 (0.43) CHRM3CHRM5PKMTAS1R3TAS1R1
SCHEMBL13699132 0.88 PKM (0.35) PKMTAS1R3TAS1R1MAPTLPAR1
SCHEMBL13699168 0.87 PKM (0.39) CHRM1CHRM3CHRM5CYP2D6PKM
SCHEMBL13699277 0.86 PKM (0.45) CYP2D6PKMTAS1R3TAS1R1SMN1; SMN2
SCHEMBL4240156 0.86 MCHR1 (0.39) CHRM1CHRM3CHRM5PKMTAS1R3
SCHEMBL13699233 0.85 ALDH1A1 (0.37) CYP2D6PKMNPSR1MAPT
SCHEMBL13699157 0.85 CHRM1 (0.44) CHRM1CHRM3CHRM5CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R CHRM1 122/4885CHRM3 168/4885CHRM5 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.